Comprehensive Platform Combines Masimo’s
Industry-leading Biosensing Capabilities with Snapdragon Wearable
Platforms to Expand the Wear OS by Google™ Ecosystem
Masimo (NASDAQ: MASI), a leading global medical innovator, and
Qualcomm Technologies, Inc., whose Snapdragon® branded platforms
power extraordinary consumer experiences, today announced that
Masimo is partnering with Qualcomm Technologies to develop a
next-generation smartwatch reference platform for original
equipment manufacturers (OEMs) building Wear OS by Google
smartwatches. The powerhouse combination of Masimo’s clinically
proven, breakthrough biosensing technologies – based on its decades
of expertise designing industry-leading hospital monitoring
solutions – and best-in-class Snapdragon wearable platforms will
help scale the wearable ecosystem. Forging the future of wearable
devices, the reference platform will allow OEMs to more efficiently
build and bring high-performing, premium smartwatches to market.
The platform will also benefit from a robust suite of Masimo health
and wellness tracking tools that consumers can trust to provide
accurate, reliable data; it will use exclusively high-performance
and ultra-low power system-on-a-chips (SoCs) alongside
industry-leading wireless and cellular communications from Qualcomm
Technologies to enable a superior connectivity experience.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240914175461/en/
Qualcomm Technologies and Masimo (Photo:
Business Wire)
Joe Kiani, Founder and CEO of Masimo, said, “We’re thrilled to
be able to partner with Qualcomm Technologies, to whom we naturally
turned to supply the chips in our own forthcoming Masimo Freedom™
wearable, to craft a truly remarkable reference platform. It’s a
platform driven by the belief that when key smartwatch components
are supplied by the leading experts in their field, the harmonious
whole produces something even greater than the sum of those
excellent parts. In short, Qualcomm Technologies and Masimo
engineers are working together to optimize the ‘guts’ of the
smartwatch. Masimo’s ability to craft precision monitoring
technologies and advanced signal processing algorithms, combined
with meticulously engineered, high-performing, low-power Snapdragon
systems, is a compelling foundation. We expect this new wearable
platform to supercharge smartwatch OEMs’ abilities to create
competitive, desirable smartwatches for consumers everywhere. I
look forward to partnering with a company as well known for its
commitment to innovation as Masimo.”
Dino Bekis, Vice President and General Manager, Wearables and
Mixed Signal Solutions at Qualcomm Technologies, Inc., said,
“Beginning with Snapdragon W5+ Gen 1, this collaboration will
significantly broaden the range of smartwatch choices for consumers
and further enhance the already exceptional Wear OS experience.
With these reference designs, OEMs will benefit from robust,
production-ready designs, incorporating Masimo’s state-of-the-art
biosensing technology and Qualcomm Technologies’ leading Snapdragon
wearable platforms. It will ultimately enable them to seamlessly
bring their smartwatches to market rapidly and at scale.”
OEMs who adopt the new reference platform will continue to
design and produce their new smartwatches’ physical exteriors and
have creative control over the appearance of the user interface.
The devices’ interiors, including Snapdragon wearable platforms and
Masimo biosensors, will be designed, provided, and tested by Masimo
to ensure premium performance and an unmatched user experience.
Health and wellness capabilities will feature the same biosensing
innovations and analytics that power Masimo W1® and forthcoming
Masimo Freedom – technology based on Masimo’s clinically proven,
industry-leading Signal Extraction Technology® (SET®). The Masimo
reference platform will make all of these components, features, and
benefits available for Wear OS smartwatch manufacturers in an
easy-to-implement, standardized package.
Snapdragon is a trademark or registered trademark of Qualcomm
Incorporated. Snapdragon is a product of Qualcomm Technologies,
Inc. and/or its subsidiaries.
Wear OS by Google is a trademark of Google LLC.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.1
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,2 improve CCHD screening in
newborns,3 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.4-5 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,6 and is
the primary pulse oximetry at all 10 top U.S. hospitals as ranked
in the 2024 Newsweek World’s Best Hospitals listing.7 In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013,
Masimo introduced the Root® Patient Monitoring and Connectivity
Platform, built from the ground up to be as flexible and expandable
as possible to facilitate the addition of other Masimo and
third-party monitoring technologies; key Masimo additions include
Next Generation SedLine® Brain Function Monitoring, O3® Regional
Oximetry, and ISA™ Capnography with NomoLine® sampling lines.
Masimo’s family of continuous and spot-check monitoring Pulse
CO-Oximeters® includes devices designed for use in a variety of
clinical and non-clinical scenarios, including tetherless, wearable
technology, such as Radius-7®, Radius PPG®, and Radius VSM™,
portable devices like Rad-67®, fingertip pulse oximeters like
MightySat® Rx, and devices available for use both in the hospital
and at home, such as Rad-97® and the Masimo W1® Medical Watch.
Masimo hospital and home automation and connectivity solutions are
centered around the Masimo Hospital Automation™ platform, and
include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo
ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing
portfolio of health and wellness solutions includes Radius Tº® and
Masimo W1 Sport. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website. Comparative studies
include independent and objective studies which are comprised of
abstracts presented at scientific meetings and peer-reviewed
journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar.
- Estimate: Masimo data on file.
-
https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the future development, efficiency, potential performance
and adoption of the new Masimo reference platform (the “Platform”)
and Masimo’s collaboration with Qualcomm. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of
which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as
a result of various risk factors, including, but not limited to:
risks related to our belief that Masimo's unique noninvasive
measurement technologies, including the Platform, contribute to
accurate, reliable data; risks related to our belief that Masimo
noninvasive medical breakthroughs provide cost-effective solutions
and unique advantages; risks related to the assumption that the
Platform will be available for integration into future OEM
smartwatches; risks related to our belief that the Platform and
OEMs will benefit from the collaboration with Qualcomm; risks
related to COVID-19; as well as other factors discussed in the
"Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained
for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240914175461/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Grafico Azioni Masimo (NASDAQ:MASI)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Masimo (NASDAQ:MASI)
Storico
Da Mar 2024 a Mar 2025
